WassimHFaresMD

Critical Care Medicine, Pleural Disease, Pulmonary Vascular Medicine

Assistant Professor, Internal Medicine, Yale University School of Medicine

Dr. Fares is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of North Carolina HospitalsFellowship, Pulmonary Disease and Critical Care Medicine, 2008 - 2011
St Vincent Charity Medical CenterResidency, Internal Medicine, 2001 - 2004
American University of Beirut Faculty of MedicineClass of 2000

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014

PubMed

6 citations
Reduced RVSWI Is Associated With Increased Mortality in Connective Tissue Disease Associated Pulmonary Arterial Hypertension.
Katharine R. Clapham, Kristin B. Highland, Youlan Rao, Wassim H. Fares
Frontiers in Cardiovascular Medicine. 2020-04-30
2 citations
PECAM-1 is Associated WithOutcomes and Response to Treatment in Pulmonary Arterial Hypertension.
Katharine R. Clapham, Youlan Rao, Sandeep Sahay, Maor Sauler, Patty J. Lee
The American Journal of Cardiology. 2020-04-29
14 citations
Primary cardiac hospitalizations in pulmonary arterial hypertension: Trends and outcomes from 2001 to 2014
Eileen M. Harder, Aeron Small, Wassim H. Fares
Respiratory Medicine. 2020-01-01

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung DiseaseOctober 31st, 2024